Biogen Settles MS Kickback Suit for $900M

Biogen has settled a whistleblower suit regarding kickbacks for its line of multiple sclerosis (MS) drugs. The company was sued for allegedly paying clinicians kickbacks when they prescribed its drugs Tecfidera, Tysabri, and Avonex. The settlement comes as competition from Novartis and Ocrevus closes in on Biogen’s MS drugs

According to Angus Liu, “Facing intense competition from generics and newer therapies, Tecfidera sales slid 18% to $398 million in the second quarter from $488 million the same period last year. Tecfidera did see a quarterly sales uptick in the U.S., but Chief Financial Officer Michael McDonnell noted during a Wednesday call that this was the result of channel dynamics and that Biogen expects the drug’s sales to decline throughout 2022.”

To read more, click here.

(Source: Fierce Pharma, July 20th, 2022)